Home Stock

Stock Research: ALK-Abelló

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

ALK-Abelló

CPH:ALK B DK0060027142
45
  • Value
    14
  • Growth
    48
  • Safety
    Safety
    92
  • Combined
    41
  • Sentiment
    54
  • 360° View
    360° View
    45
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

ALK-Abello A/S is a Denmark-based pharmaceutical company specializing in allergy treatment, prevention, and diagnosis. Its main businesses include allergy vaccines (tablet, sublingual, subcutaneous), emergency treatments for anaphylaxis, and allergy diagnostics products like skin-prick tests. The company operates worldwide through subsidiaries, production units, and distributors in countries such as Austria, Canada, France, Italy, the Netherlands, Poland, Spain, Switzerland, the United States, and China. In the last fiscal year, the company had 2753 employees, a market cap of $6128 millions, profits of $493 millions, and revenue of $769 millions.

more

ANALYSIS: With an Obermatt 360° View of 45 (better than 45% compared with alternatives), overall professional sentiment and financial characteristics for the stock ALK-Abelló are below the industry average. The 360° View is based on consolidating four consolidated indicators, with half below and half above average for ALK-Abelló. The consolidated Sentiment Rank has a good rank of 54, which means that professional investors are more optimistic about the stock than for 54% of alternative investment opportunities. It also rates well regarding its financing structure, with the consolidated Safety Rank at 92 or better than 92% of its peers when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the stock is expensive and expects low growth. The consolidated Value Rank is only 14, meaning that the share price of ALK-Abelló is on the high side, compared with indicators such as revenues, profits, and invested capital. The company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, invested capital growth,and stock returns, with its Growth Rank at 48. ...read more

more
Strongest Rank Price vs. Earnings (P/E)
Weakest Rank Liquidity
Country Denmark
Industry Pharmaceuticals
Size Medium
Website alk.net
Index
ALK-Abelló stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 17-Sep-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
14 1 5 1
Growth
48 86 63 77
Safety
Safety
92 73 64 27
Sentiment
54 70 56 58
360° View
360° View
45 81 41 30
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
75 80 72 55
Opinions Change
50 6 17 50
Pro Holdings
n/a 55 34 30
Market Pulse
52 87 91 79
Sentiment
54 70 56 58
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
14 1 5 1
Growth
48 86 63 77
Safety Safety
92 73 64 27
Combined
41 73 32 15
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
28 7 22 15
Price vs. Earnings (P/E)
7 9 12 3
Price vs. Book (P/B)
21 1 14 3
Dividend Yield
52 1 1 1
Value
14 1 5 1
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
86 87 67 65
Profit Growth
52 74 86 96
Capital Growth
43 76 10 11
Stock Returns
26 61 56 72
Growth
48 86 63 77
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
78 67 70 51
Refinancing
62 25 33 26
Liquidity
94 90 62 34
Safety Safety
92 73 64 27

Similar Stocks

Discover high‑ranked alternatives to ALK-Abelló and broaden your portfolio horizons.

Fresenius

GER:FRE
Country: Germany
Industry: Health Care Services
Size: X-Large
Full Stock Analysis

Strabag

VIE:STR
Country: Austria
Industry: Construction & Engineering
Size: X-Large
Full Stock Analysis

Faes Farma

MCE:FAE
Country: Spain
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Yara International

OSL:YAR
Country: Norway
Industry: Fertilizers & Agricultural Chemicals
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

The value case is weak (expensive and low Growth Rank), but sentiment is strong and financing is safe. This scenario may indicate future growth not yet in current financials. This is a speculative choice for investors with a high-risk appetite who are betting on the positive sentiment and safe financing to sustain a long-term turnaround.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews